Premium
Non convulsive refractory status epilepticus induced by thiocolchicoside (TCC) intrathecal injection: A case report
Author(s) -
Evangelista Giacomo,
Dono Fedele,
Consoli Stefano,
Pozzilli Valeria,
Calisi Dario,
Russo Mirella,
D'Orazio Claudia,
D'Andreagiovanni Anna,
Montesano Giovanna,
Rapini Sabina,
Caulo Massimo,
Onofrj Marco,
Anzellotti Francesca
Publication year - 2022
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.15240
Subject(s) - status epilepticus , medicine , refractory (planetary science) , somnolence , context (archaeology) , anesthesia , epilepsy , complication , neurological disorder , pediatrics , adverse effect , central nervous system disease , surgery , psychiatry , paleontology , physics , astrobiology , biology
TCC is a semisynthetic molecule widely used in clinical settings as a pain killer and myorelaxant. Several neurological side effects have been reported in association with TCC treatment including somnolence, confusion and seizure, the latter in a lower percentage of patients. Some previous reports described seizure onset after TCC intake in adulthood. However, major epileptological complication, namely status epilepticus, has never been previously reported in association with TCC treatment. In our report, we describe a case of acute refractory non‐convulsive status epilepticus (NCSE) in the context of a TCC‐induced acute toxic encephalopathy (ATE) in a woman without any previous neurological or physical comorbidities.